“I think the most notable finding is that we did see continued benefit from each injection series,” says Matthew J. Ziegelmann, MD.
In this video, Matthew J. Ziegelmann, MD, discusses notable findings from the Urology paper, “Incremental Treatment Response by Cycle With Collagenase Clostridium Histolyticum for Peyronie's Disease: a Pooled Analysis of Two Phase 3 Trials.” Ziegelmann is a urologist at Mayo Clinic in Rochester, Minnesota.
I think the most notable finding is that we did see continued benefit from each injection series. We tended to see the most robust improvements with the first couple of injection series. That's consistent with what's been shown in some of the previous clinical work. But those patients who didn't respond initially did have a potential of response with subsequent injections. I think if we look at the actual data, if you look at the percentage of patients who didn't respond to the first 2 injection series - we defined response as at least a 20% reduction in curve - of those patients who didn't meet that criteria with the first 2 injections series, we saw that 42% went on to have a subsequent response with the second 2. That's not 100%, but that's a good portion of the patients. That's useful when patients say, "I didn't respond to these initial injections; should we just stop the therapy? Is it worth it?" And we can say, "Here are the data. Here's what we have. We know that not everyone's going to respond. But this is your likelihood of success." It does give us more information to say, "There is incremental response. We can continue to see response even if you weren't an early responder." I think that's meaningful for counseling our patients.
This transcription was edited for clarity.